The potential of CAR T cell therapy for prostate cancer
Nature Reviews Urology, Published online: 08 July 2021; doi:10.1038/s41585-021-00488-8Chimeric antigen receptor T cell immunotherapy for prostate cancer has the potential to be combined with other treatment modalities, such as androgen deprivation therapy, radiotherapy or chemotherapy; furthermore, new developments could improve the efficacy of chimeric antigen receptor T cell therapy and this treatment could also be applied as focal therapy for this disease.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Philipp Wolf Jamal Alzubi Christian Gratzke Toni Cathomen Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Prostate Cancer | Urology & Nephrology